Prosecution Insights
Last updated: October 27, 2026

Kimberly Catherine Breen, USPTO Patent Examiner

Listed by the USPTO as BREEN, KIMBERLY CATHERINE

Tech Center 1600 • Art Units: 1651 1653 1657 1675

This examiner grants 24% of resolved cases

Analysis

BREEN, KIMBERLY CATHERINE works in Tech Center 1600 and art unit 1651, with 84 resolved cases. The allowance rate is 23.8%, and the median time to allowance is 1285 days. The interview lift is 56.3%, indicating a strong positive association between interviews and allowance despite the limited allowance rate.

The listed companies are Danisco US Inc., CJ CheilJedang Corporation, and Janssen Pharmaceuticals Inc. The listed firms are Meunier Carlin & Curfman LLC, TROUTMAN PEPPER LOCKE LLP, and Nevrivy Patent Law Group P.L.L.C. Practitioners may want to give interviews a central role in response planning while accounting for the challenging allowance record.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

23.8%
Allow Rate
-36.2% vs TC avg
143
Total Applications
+56.3%
Interview Lift
1285
Avg Prosecution Days
Based on 84 resolved cases, 2023–2026

Rejection Statute Breakdown

9.7%
§101 Eligibility
9.3%
§102 Novelty
34.9%
§103 Obviousness
31.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18844384 MUTANT L-THREONINE-RELEASING PROTEIN AND METHOD FOR PRODUCING L-THREONINE USING SAME Non-Final OA CJ CHEILJEDANG CORPORATION
18681047 METHOD FOR PRODUCTION OF AMMONIA, USING INORGANIC NANOPARTICLE-MICROBIAL COMPLEX Final Rejection KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
17628903 WASHING AND CLEANING AGENTS HAVING IMPROVED ENZYME STABILITY Non-Final OA Henkel AG & Co. KGaA
16959998 PROBIOTICS, METABOLITES, AND USES THEREOF Final Rejection California Institute of Technology
18774152 OPTOGENETIC CONTROL OF MICROBIAL CO-CULTURE POPULATIONS Non-Final OA The Trustees of Princeton University
18566018 METHODS AND COMPOSITIONS RELATED TO A MODIFIED METHYLTRANSFERASE Non-Final OA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
18248392 COLLAGEN BIOMATERIAL Final Rejection Hide Biotech Ltd

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Kimberly Catherine Breen's allowance rate?

23.8% of resolved applications examined by Kimberly Catherine Breen were allowed (84 resolved cases), compared with 31.6% across Art Unit 1651 over the last five years.

Does an interview help with examiner Kimberly Catherine Breen?

This examiner's interview lift is +56.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Kimberly Catherine Breen take to allow a patent?

Applications allowed by Kimberly Catherine Breen took 1,285 days on average from filing to allowance.

Which art unit does examiner Kimberly Catherine Breen work in?

Kimberly Catherine Breen examines applications in Art Unit 1651 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month